MOLECULAR TEMPLATES INC (MTEM)
US6085502085 - Common Stock
MTEM gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. MTEM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, MTEM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year MTEM has reported negative net income.
In the past year MTEM has reported a negative cash flow from operations.
MTEM had negative earnings in each of the past 5 years.
In the past 5 years MTEM always reported negative operating cash flow.
1.2 Ratios
MTEM has a better Return On Assets (-22.94%) than 78.29% of its industry peers.
MTEM's Return On Equity of -192.74% is on the low side compared to the rest of the industry. MTEM is outperformed by 71.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.94% | ||
| ROE | -192.74% | ||
| ROIC | N/A |
ROA(3y)-53.73%
ROA(5y)-55.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MTEM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MTEM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MTEM has been increased compared to 1 year ago.
MTEM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for MTEM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
MTEM has an Altman-Z score of -17.10. This is a bad value and indicates that MTEM is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -17.10, MTEM is doing worse than 85.81% of the companies in the same industry.
There is no outstanding debt for MTEM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.1 |
ROIC/WACCN/A
WACC9.67%
2.3 Liquidity
MTEM has a Current Ratio of 0.97. This is a bad value and indicates that MTEM is not financially healthy enough and could expect problems in meeting its short term obligations.
MTEM has a Current ratio of 0.97. This is amonst the worse of the industry: MTEM underperforms 88.89% of its industry peers.
MTEM has a Quick Ratio of 0.97. This is a bad value and indicates that MTEM is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of MTEM (0.97) is worse than 88.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.97 | ||
| Quick Ratio | 0.97 |
3. Growth
3.1 Past
MTEM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.74%, which is quite impressive.
MTEM shows a strong growth in Revenue. In the last year, the Revenue has grown by 190.06%.
The Revenue has been growing by 33.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)93.74%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q87.56%
Revenue 1Y (TTM)190.06%
Revenue growth 3Y44.86%
Revenue growth 5Y33.95%
Revenue growth Q2Q168.81%
3.2 Future
Based on estimates for the next years, MTEM will show a very negative growth in Earnings Per Share. The EPS will decrease by -19.70% on average per year.
MTEM is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -10.69% yearly.
EPS Next Y-113.87%
EPS Next 2Y-60.82%
EPS Next 3Y-21.57%
EPS Next 5Y-19.7%
Revenue Next Year-78.12%
Revenue Next 2Y-84.66%
Revenue Next 3Y-46.28%
Revenue Next 5Y-10.69%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MTEM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTEM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as MTEM's earnings are expected to decrease with -21.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-60.82%
EPS Next 3Y-21.57%
5. Dividend
5.1 Amount
No dividends for MTEM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MOLECULAR TEMPLATES INC
NASDAQ:MTEM (5/17/2024, 7:14:56 PM)
After market: 1.42 -0.03 (-2.07%)1.45
-0.05 (-3.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.54M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.94% | ||
| ROE | -192.74% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.97 | ||
| Quick Ratio | 0.97 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)93.74%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-113.87%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)190.06%
Revenue growth 3Y44.86%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y